دورية أكاديمية
Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya.
| العنوان: | Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya. |
|---|---|
| المؤلفون: | Hassan AS; KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya. ahassan@kemri-wellcome.org, Mwaringa SM, Obonyo CA, Nabwera HM, Sanders EJ, Rinke de Wit TF, Cane PA, Berkley JA |
| المصدر: | AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2013 Jan; Vol. 29 (1), pp. 129-35. Date of Electronic Publication: 2012 Sep 11. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mary Ann Liebert Country of Publication: United States NLM ID: 8709376 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1931-8405 (Electronic) Linking ISSN: 08892229 NLM ISO Abbreviation: AIDS Res Hum Retroviruses Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Larchmont, NY : Mary Ann Liebert Original Publication: [New York] : Mary Ann Liebert, [c1987- |
| مواضيع طبية MeSH: | Anti-HIV Agents/*therapeutic use , HIV Infections/*drug therapy , HIV-1/*drug effects, Adult ; Cohort Studies ; Cross-Sectional Studies ; Drug Resistance, Viral/genetics ; Female ; HIV Infections/virology ; HIV-1/genetics ; Humans ; Kenya/epidemiology ; Male ; Molecular Sequence Data ; Prevalence ; Rural Population/statistics & numerical data |
| مستخلص: | Low levels of HIV-1 transmitted drug resistance (TDR) have previously been reported from many parts of sub-Saharan Africa (sSA). However, recent data, mostly from urban settings, suggest an increase in the prevalence of HIV-1 TDR. Our objective was to determine the prevalence of TDR mutations among HIV-1-infected, antiretroviral (ARV)-naive adults enrolling for care in a rural HIV clinic in Kenya. Two cross-sectional studies were carried out between July 2008 and June 2010. Plasma samples from ARV-naive adults (>15 years old) at the time of registering for care after HIV diagnosis and before starting ARVs were used. A portion of the pol subgenomic region of the virus containing the protease and part of the reverse transcriptase genes was amplified and sequenced. TDR mutations were identified and interpreted using the Stanford HIV drug resistance database and the WHO list for surveillance of drug resistance strains. Overall, samples from 182 ARV-naive adults [mean age (95% CI): 34.9 (33.3-36.4) years] were successfully amplified and sequenced. Two TDR mutations to nucleoside reverse transcriptase inhibitors [n=1 (T215D)] and protease inhibitors [n=1 (M46L)] were identified, giving an overall TDR prevalence of 1.1% (95% CI: 0.1-3.9). Despite reports of an increase in the prevalence of HIV-1 TDR in some urban settings in sSA, we report a prevalence of HIV-1 TDR of less than 5% at a rural HIV clinic in coastal Kenya. Continued broader surveillance is needed to monitor the extent of TDR in sSA. |
| References: | Antivir Ther. 2008;13 Suppl 2:25-36. (PMID: 18575189) Lancet Infect Dis. 2011 Oct;11(10):750-9. (PMID: 21802367) AIDS Res Hum Retroviruses. 2012 Sep;28(9):1033-7. (PMID: 22149307) AIDS Res Hum Retroviruses. 2009 Mar;25(3):337-42. (PMID: 19327052) PLoS One. 2009;4(3):e4724. (PMID: 19266092) Curr Opin HIV AIDS. 2011 Jul;6(4):251-7. (PMID: 21646877) AIDS. 2004 Aug 20;18(12):1653-60. (PMID: 15280776) AIDS Res Hum Retroviruses. 2011 Apr;27(4):365-72. (PMID: 21034246) AIDS. 2011 Nov 13;25(17):2183-8. (PMID: 21860346) J Infect Dis. 2008 Mar 15;197(6):867-70. (PMID: 18269317) Antivir Ther. 2008;13(5):625-39. (PMID: 18771046) AIDS. 2005 Jan 3;19(1):1-14. (PMID: 15627028) AIDS Res Hum Retroviruses. 2011 Jan;27(1):5-12. (PMID: 21091377) Lancet Infect Dis. 2009 Jul;9(7):409-17. (PMID: 19555900) Emerg Themes Epidemiol. 2005 Sep 10;2:9. (PMID: 16153307) Lancet. 2008 May 10;371(9624):1603-11. (PMID: 18468544) AIDS. 2011 Apr 24;25(7):905-10. (PMID: 21399479) J Med Virol. 2011 Sep;83(9):1508-13. (PMID: 21739439) J Virol. 2008 Jun;82(11):5510-8. (PMID: 18353964) Lancet Infect Dis. 2011 May;11(5):363-71. (PMID: 21354861) Trop Med Int Health. 2012 Jan;17(1):82-93. (PMID: 22943164) Antivir Ther. 2008;13 Suppl 2:77-82. (PMID: 18575194) Antivir Ther. 2008;13 Suppl 2:101-7. (PMID: 18575198) AIDS Res Hum Retroviruses. 2012 Feb;28(2):220-4. (PMID: 21770741) Antivir Ther. 2008;13 Suppl 2:89-94. (PMID: 18575196) PLoS Comput Biol. 2009 Nov;5(11):e1000581. (PMID: 19956739) Lancet Infect Dis. 2012 Apr;12(4):307-17. (PMID: 22036233) AIDS Res Hum Retroviruses. 2008 Jun;24(6):889-95. (PMID: 18544019) Antivir Ther. 2008;13 Suppl 2:83-7. (PMID: 18575195) PLoS Med. 2006 Apr;3(4):e124. (PMID: 16519553) AIDS. 2007 Jan 11;21(2):215-23. (PMID: 17197813) AIDS Res Hum Retroviruses. 2011 Apr;27(4):377-82. (PMID: 20954839) Methods Mol Biol. 2011;665:123-32. (PMID: 21116799) J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1570-3. (PMID: 15577410) AIDS Res Hum Retroviruses. 2009 Dec;25(12):1211-7. (PMID: 19954302) Clin Infect Dis. 2005 Feb 1;40(3):468-74. (PMID: 15668873) |
| معلومات مُعتمدة: | 092654 United Kingdom Wellcome Trust; WT083579MA United Kingdom WT_ Wellcome Trust; WT089351MA United Kingdom WT_ Wellcome Trust |
| سلسلة جزيئية: | GENBANK HQ441597; HQ441598; HQ441599; HQ441600; HQ441601; HQ441602; HQ441603; HQ441604; HQ441605; HQ441606; HQ441607; HQ441608; HQ441609; HQ441610; HQ441611; HQ441612; HQ441613; HQ441614; HQ441615; HQ441616; HQ441617; HQ441618; HQ441619; HQ441620; HQ441621; HQ441622; HQ441623; HQ441624; HQ441625; HQ441626; HQ441627; HQ441628; HQ441629; HQ441630; HQ441631; HQ441632; HQ441633; HQ441634; HQ441635; HQ441636; HQ441637; HQ441638; HQ441639; HQ441640; HQ441641; HQ441642; HQ441643; HQ441644; HQ441645; HQ441646; HQ441647; HQ441648; HQ441649; HQ441650; HQ441651; HQ441652; HQ441653; HQ441654; HQ441655; HQ441656; HQ441657; HQ441658; HQ441659; HQ441660; HQ441661; HQ441662; HQ441663; HQ441664; HQ441665; HQ441666; HQ441667; HQ441668; HQ441669; HQ441670; HQ441671; HQ441672; HQ441673; HQ441674; HQ441675; HQ441676; HQ441677; HQ441678; HQ441679; HQ441680; HQ441681; HQ441682; HQ441683; HQ441684; HQ441685; HQ441686; HQ441687; HQ441688; HQ441689; HQ441690; HQ441691; HQ441692; HQ441693; HQ441694; HQ441695; HQ441696; HQ441697; HQ441698; HQ441699; HQ441700; HQ441701; HQ441702; HQ441703; HQ441704; HQ441705; HQ441706; HQ441707; HQ441708; HQ441709; HQ441710; HQ441711; HQ441712; HQ441713; HQ441714; HQ441715; HQ441716; HQ441717; JQ698340; JQ698341; JQ698342; JQ698343; JQ698344; JQ698345; JQ698346; JQ698347; JQ698348; JQ698349; JQ698350; JQ698351; JQ698352; JQ698353; JQ698354; JQ698355; JQ698356; JQ698357; JQ698358; JQ698359; JQ698360; JQ698361; JQ698362; JQ698363; JQ698364; JQ698365; JQ698366; JQ698367; JQ698368; JQ698369; JQ698370; JQ698371; JQ698372; JQ698373; JQ698374; JQ698375; JQ698376; JQ698377; JQ698378; JQ698379; JQ698380; JQ698381; JQ698382; JQ698383; JQ698384; JQ698385; JQ698386; JQ698387; JQ698388; JQ698389; JQ698390; JQ698391; JQ698392; JQ698393; JQ698394; JQ698395; JQ698396; JQ698397; JQ698398; JQ698399; JQ698400; JQ698401; JQ698402; JQ698403; JQ698404; JQ698405; JQ698406; JQ698407; JQ698408; JQ698409; JQ698410; JQ698411; JQ698412; JQ698413; JQ698414; JQ698415; JQ698416; JQ698417; JQ698418; JQ698419; JQ698420; JQ698421; JQ698422; JQ698423; JQ698424; JQ698425; JQ698426; JQ698427; JQ698428; JQ698429; JQ698430 |
| المشرفين على المادة: | 0 (Anti-HIV Agents) |
| تواريخ الأحداث: | Date Created: 20120821 Date Completed: 20130605 Latest Revision: 20211021 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC3537300 |
| DOI: | 10.1089/AID.2012.0167 |
| PMID: | 22900472 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1931-8405 |
|---|---|
| DOI: | 10.1089/AID.2012.0167 |